Patrick McNamara Named Chief Commercial Officer at Yunu, Driving Growth in Trial Imaging for Pharma
CARY, NC / ACCESS Newswire / June 24, 2025 / Yunu, the creator and leader in cloud-native imaging workflows for clinical trials, proudly announces Patrick McNamara as its new Chief Commercial Officer. With over two decades of experience in clinical research and business development, McNamara has played a pivotal role in Yunu's rapid expansion across the pharmaceutical, biotech, and contract research organization (CRO) sectors.
McNamara's appointment reinforces Yunu's commitment to advancing transformative clinical trial imaging solutions at scale. His deep industry knowledge is built upon years of hands-on leadership as the prior VP of Business Development for the clinical endpoint division of a major CRO as well as key oversight of commercial and operational teams. His extensive experience and strategic vision accelerate Yunu's ability to deeply engage with sponsors and CROs in Yunu's industry-wide effort to transform trialimaging workflows, accelerate new therapies, and improve data quality.
"We are thrilled to appoint Patrick McNamara as our Chief Commercial Officer," said Jeff Sorenson, CEO & Co-founder of Yunu. "Patrick's unique perspective allows Yunu to orient our teams around the specific needs and processes of pharma while also fine-tuning our go-to-market as we continue to deliver game-changing trial acceleration and transparency."
Yunu recently unveiled a groundbreaking software release that empowers pharma sponsors to rapidly configure new studies, connect to readers, and ensure real time access to their imaging data within their primary data systems. This advancement underscores Yunu's role as an innovator and leader in harmonizing multi-site trials, reducing complexity, and accelerating trial imaging timelines.
Yunu is also managing all imaging endpoints delivered to sponsors at more than 25% of NCI-designated Comprehensive Cancer Centers. The platform's impact will be discussed during a special session with City of Hope leadership in addition to showcasing these latest advancements during the 17th Annual AACI CRI Meeting in Chicago from Monday, June 23rd, to Wednesday, June 25th.
ABOUT YUNUYunu enables life sciences organizations to streamline imaging workflows, improve accuracy, and accelerate timelines. Yunu's platform supports clinical trials across various therapeutic areas, offering scalability and flexibility for organizations of all sizes. For more information, visit yunu.io and follow us on LinkedIn or X @Yunu_Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Five University of Colorado Cancer Center Advancements That Changed the Game for Patients
As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease. AURORA, Colo., June 24, 2025 /PRNewswire/ -- The University of Colorado Cancer Center this year celebrates its 40th anniversary, highlighting significant advances in research and innovations that include new therapies, treatments and insights into cancer prevention. "For 40 years, the CU Cancer Center has been the cornerstone of cancer research, innovation and care in Colorado and the Rocky Mountain region," says CU Anschutz Chancellor Donald Elliman. "We're not only delivering world-class care today – we're bringing new possibilities into reach and redefining the cancer treatment of the future." The CU Cancer Center, founded in 1985, became a National Cancer Institute-designated cancer center in 1988 under the leadership of its founding director, Paul Bunn, MD. In 1997, it had the further distinction of being named one of 57 NCI Comprehensive Cancer Centers. The "comprehensive" designation recognizes the center's strengths in basic, translational, clinical and population science research, as well as leadership and resources devoted to community outreach and engagement and cancer research training and education. Here are five innovations that helped make the CU Cancer Center part of the worldwide cancer conversation. Multidisciplinary clinics It can take an army of specialists to treat a cancer patient, and in the early days of the CU Cancer Center, that meant multiple appointments on multiple days with specialists who may or may not have been aligned on a treatment plan. That changed in 2012, when Richard Schulick, MD, MBA, became chair of the CU Department of Surgery. Schulick brought with him the concept of a multidisciplinary clinic for pancreatic and biliary cancers in which a patient comes in for one day and is seen by multiple specialists — including surgical oncologists, medical oncologists, radiation oncologists, pathologists, dietitians and genetic counselors. They then meet that same day to develop a comprehensive treatment plan. When Schulick became director of the CU Cancer Center in 2018, he expanded the multidisciplinary clinics. There are now clinics for 12 types of cancer. "It was incredible to suddenly have all these doctors come together to give me answers," says patient Val Beck, who was treated for colorectal cancer at the CU Cancer Center in 2023. "They never lied to me. They told me that my type of cancer was scary, and they said it was going to be hard. But they also said they were going to ensure I received the best treatment possible." A new treatment for acute myeloid leukemia Thanks in large part to early work by CU Cancer Center researchers Craig Jordan, PhD, and Daniel Pollyea, MD, MS, patients with the blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome have a new treatment option that has fewer side effects and has been shown to increase longevity. In 2020, the Food and Drug Administration granted regular approval to the drug venetoclax (Venclexta), in combination with a low-dose chemotherapy treatment, for the treatment of AML in older adults who are unfit for intensive chemotherapy. The drug works by targeting and inhibiting the Bcl-2 protein, a key component of leukemia stem cells. Of 31 evaluable patients treated with venetoclax in a 2018 clinical trial conducted by Pollyea and Jordan, 20 experienced complete remission, while eight had a complete response but with continued low blood counts. The FDA granted the drug preliminary approval based on those clinical trials and a subsequent randomized study. Pollyea and Jordan still are researching the drug to determine how it could be even more effective, including new and upcoming studies on its effects in younger populations as well as research to tackle both upfront and post-treatment resistance. "Some of our hypotheses about how we could use venetoclax weren't necessarily part of the conventional wisdom five years ago," Pollyea says. "It's exciting to see how many of our theories were correct, and to see how others in the hematology community have built out parts of the story that are very complementary and exciting. We're all learning from each other." Lowering the screening age for colorectal cancer After an alarming rise in colorectal cancer in people younger than 50, the United States Preventive Services Task Force in 2021 lowered the recommended screening age for the cancer from 50 to 45 for people at normal risk. One of the key figures behind the move was Andrea Dwyer, program director of the Colorado Cancer Screening Program at the CU Cancer Center, who worked alongside the American Cancer Society to expand the screening population. "The change in the guideline is going to take several years to fully catch on with people in the way we need it to, but we're already starting to see some people start their screening at age 45," Dwyer says. "We still have a lot of work to do on awareness of the need to start screening earlier. Colorectal cancer does happen among young adults, even teenagers, and we don't know why." Cell-based immune therapies Though many cancers are still effectively treated with chemotherapy and radiation, some cancers — especially blood cancers — have seen a revolution with treatments using the patient's own immune cells to attack cancer cells. The CU Cancer Center is at the forefront of this evolving science. Tumor-infiltrating lymphocyte therapy, for example — which is being studied by CU Cancer Center researchers including Eduardo Davila, PhD — involves surgically removing tumor tissue from a patient's body and extracting activated T cells from the tissue. The cells are multiplied in the lab, then reinfused into the patient's body to attack tumors. The CU Cancer Center also is a national leader in chimeric antigen receptor T cell (CAR T) therapy, a powerful treatment in which a patient's immune cells are removed from their body, taken to a lab and genetically engineered to become fighter cells, then injected back into the patient, where they seek out and destroy cancer cells. One of the leaders in this effort is CU Cancer Center member Terry Fry, MD, executive director of the Gates Institute, a translational research institute on the CU Anschutz Medical Campus that produces CAR T and other cellular therapies for research. Gates recently launched a clinical trial of a CAR for pediatric patients with relapsed or refractory pre B-cell acute lymphoblastic leukemia (B-ALL). Elsewhere on campus, M. Eric Kohler, MD, PhD, and Catherine Danis, PhD, recently published research on a next-generation CAR T therapy called ALA-CART (adjunctive LAT-activating CAR-T cells), which optimizes CAR-T cells to more effectively eliminate cancer cells, including those that have been able to hide from traditional CAR-T cells. The therapy also is being studied at the Flint Animal Cancer Center at Colorado State University, one of the CU Cancer Center's clinical partners. A trial launched in 2023 at Flint is testing the effectiveness of CAR T treatment on naturally occurring osteosarcoma in pet dogs. "These are cells that can potentially live in your body for months or even years," says Steven Dow, DVM, PhD, "The cells eradicate the cancerous tumor with the aim to make sure it doesn't recur." Testing for gene mutations in lung cancer Not all lung cancers are created equal, and researchers at the CU Cancer Center's Thoracic Oncology Research Initiative helped to pioneer the practice of testing for genetic mutations within lung cancer cells to determine which patients are likely to respond to specific medications — in some cases a single daily oral medication that allows someone diagnosed with lung cancer to enjoy a better quality of life. Research into fusions and mutations by CU Cancer Center members Robert Doebele, MD, PhD, Marileila Garcia, PhD, and D. Ross Camidge, MD — as well as early research in the field by Paul Bunn, MD, the cancer center's first director — has helped thousands of lung cancer patients worldwide. "We're fortunate that in Colorado, we were one of the early adopters of doing routine molecular testing of our lung cancer patients, to put them into different buckets based on the mutations in their cancer," Camidge says. "That allowed us to say, 'OK, there are five people in front of us, and they all have lung cancer, but really, they have different subtypes of lung cancer, and they need different treatments.' When you personalize that treatment, you start to really get transformative control of the cancer." About the University of Colorado Anschutz Medical CampusThe University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes, and two nationally ranked independent hospitals - UCHealth University of Colorado Hospital and Children's Hospital Colorado - that treat more than two million adult and pediatric patients each year. Innovative, interconnected and highly collaborative, the University of Colorado Anschutz Medical Campus delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by over $705 million in research grants. For more information, visit Contact: Laura Kelley, University of Colorado Anschutz Medical Campus View original content to download multimedia: SOURCE University of Colorado Anschutz Medical Campus Sign in to access your portfolio
Miami Herald
2 hours ago
- Miami Herald
The Rise of Walkable Suburbs: Where Raleigh-Durham Families Are Heading Next
CHAPEL HILL, NC / ACCESS Newswire / June 24, 2025 / More families in the Triangle are following the nationwide trend and looking for homes in walkable suburbs. While schools and square footage are still major considerations, other aspects of family life are influencing relocation decisions. For instance, if you're a young family, you probably want to be able to walk to parks, coffee shops, and grocery stores. Maybe you desire a healthier, more sustainable lifestyle, or perhaps you simply crave the convenience of getting around safely without a car. Either way, walkability is fast becoming one of the most searched-for features in real estate. If you're looking to buy, here are some stand-out areas where families are going. Fuquay-Varina: the Hottest Local Market Fuquay-Varina is one of the fastest-growing towns in the Triangle. Specifically, its ZIP code 27526 beat over 41,000 others and ranked 20th nationally, according to a study by Opendoor, and it's easy to see why. It has a low crime rate and a small-town feel, with around 45,000 residents, almost double that of 10 years ago. There's plenty of shopping, entertainment, dining, and family-sized homes, with new developments underway to account for the swelling population, so when you begin your local Raleigh-Durham real estate search, Fuquay-Varina should be on your radar. Holly Springs: Great for Community Holly Springs has secured itself as a firm favorite for young families thanks to its clean, organized, and kid-friendly spaces. It's a safe neighborhood, with multiple parks, walkways, and recreational centers. Downtown, you'll find a great variety of shops, cafes, restaurants, and more. The schools are highly rated, and most areas are connected by sidewalks and greenways. It's relatively easy to get around on foot, with a Walk Score of 65. Apex: Historic Charm Apex is famous for being a fantastic place to raise a family, emphasized by its local motto, being the "Peak of Good Living". There's a good dose of Southern charm in this safe suburban neighbourhood, with a pedestrian-friendly downtown and amazing walkability between schools and residential areas. Plus, for weekends in nature, there are biking and hiking trails nearby and Jordan Lake State Recreation Area for windsurfing, boating, and other outdoor activities. The Walk Score here is 74, meaning it's very walkable. Durham: Urban Walkability If you're looking for a mix of walkability and city vibe, Durham may be more up your street. In places like Trinity Park, Old West Durham, and Downtown, you can easily live within walking distance of markets, schools, parks, restaurants, and music venues. You still get the close-knit neighborhood feel, but without sacrificing the culture and convenience that comes with inner-city living. Downtown Durham has a Walk Score of 94, earning it the coveted status of Walker's Paradise. This means you can easily take care of daily errands without a car. Endnote Walkable suburbs are in high demand in the Raleigh-Durham area, especially with families. Places like Fuquay-Varina, Holly Springs, and Apex provide plenty of green space, good quality living, and a strong sense of community. If you're looking for somewhere you can walk the kids to school, take a stroll downtown, and leave the car keys at home, these local neighborhoods are a good place to start. Company: Triangle House HunterName: Ryan CassidyEmail: trianglehousehunter@ 318 Cloister Ct Chapel Hill NC 27514 SOURCE: Triangle House Hunter
Miami Herald
2 hours ago
- Miami Herald
The Jeffcoat Firm Recognized as Finalist for 2025 Best Legal Innovation Award
COLUMBIA, SC / ACCESS Newswire / June 24, 2025 / The Jeffcoat Firm, a leading personal injury law firm based in South Carolina, has been named a finalist for the 2025 Best Legal Innovation Award by Daily Report. This prestigious recognition highlights the firm's commitment to leveraging technology and client-centered strategies to redefine legal services in the personal injury sector. Michael Jeffcoat started Jeffcoat Injury and Car Accident Lawyers in 1999. The firm has consistently prioritized client advocacy and legal excellence. Its innovative approach includes the integration of advanced case management systems and a robust digital presence, ensuring clients receive timely updates and comprehensive support throughout their legal journey. "Being recognized as a finalist for the Best Legal Innovation Award is a testament to our team's dedication to embracing change and continuously improving our services," said Michael Jeffcoat, who is also managing attorney of The Jeffcoat Firm. "Our goal has always been to combine traditional legal expertise with modern tools to better serve our clients." The Jeffcoat Firm's nomination underscores its role as a trailblazer in the legal industry, setting new standards for how law firms operate in the digital age. By adopting innovative solutions and maintaining a client-first philosophy, the firm has positioned itself at the forefront of legal service delivery. The winners of the 2025 Best Legal Innovation Award will be announced at the upcoming Legal Excellence Gala in Atlanta, Georgia. About The Jeffcoat Firm The Jeffcoat Firm is a South Carolina-based personal injury law firm dedicated to providing compassionate and effective legal representation. With a focus on client satisfaction and innovative practices, the firm handles a wide range of personal injury cases, including car accidents, medical malpractice, and wrongful death claims. Contact: The Jeffcoat Firm1333 Main Street, Suite 510Columbia, SC 29201Phone: (803) 373-1706Email: info@ For more information about Michael Jeffcoat and his role in founding the firm, please visit. SOURCE: The Jeffcoat Firm
